PatientsVille.com LogoPatientsVille.com

Glaucoma | Steroids After Laser Trabeculoplasty for Glaucoma

Glaucoma research study

What is the primary objective of this study?

The purpose of this study is to determine whether the choice of post-operative eye drop administered after selective laser trabeculoplasty (SLT) for glaucoma affects the efficacy in lowering intraocular pressure (IOP).

Who is eligible to participate?

Inclusion Criteria: - clinical diagnosis of glaucoma - clinician has determined that SLT laser is indicated - IOP currently >18 and was ever >21 in the past (e.g. prior to treatment) Exclusion Criteria: - prior history of uveitis - prior glaucoma surgery including glaucoma laser surgery - pregnant or 3 months post-partum

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Glaucoma

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:Prednisolone 1%Prednisolone 1% to lasered eye 4 times/day for 4.5 days

Drug:KetorolacKetorolac 0.5% to lasered eye 4 times/day for 4.5 days

Drug:Artificial TearsArtificial saline tears to lasered eye 4 times/day for 4.5 days

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Artificial TearsTopical artificial tears dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.

Non-steroidal anti-inflammatoryTopical ketorolac 0.5% dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.

SteroidTopical prednisolone 1% dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.

Study Status

Completed

Start Date: September 2009

Completed Date: September 2015

Phase: Phase 4

Type: Interventional

Design:

Primary Outcome: Intraocular Pressure (IOP) Change

Secondary Outcome: Intraocular Inflammation

Study sponsors, principal investigator, and references

Principal Investigator: Jeffrey L Goldberg, MD, PhD

Lead Sponsor: Stanford University

Collaborator: Bascom Palmer Eye Institute

More information:https://clinicaltrials.gov/show/NCT00981435

Discuss Genteal